Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- CHMP Recommends Approval for Astellas' Antibiotic Vibativ
June 13, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Nippon Chemiphar: Sales Up 14% Driven by Generics
June 13, 2011
- PMDA Proposes Fees for Regulatory Strategy Consultation Services
June 13, 2011
- FDA Approves GE Versions of Aricept from 15 Companies
June 13, 2011
- Seikagaku: Net profits Down 31.4% due to Impact of Disaster
June 13, 2011
- METI to Relax Power Use Restriction for Drug-related Companies
June 13, 2011
- JAMS, PSJ to Directly Exchange Opinions on Switch OTC Drug Candidates
June 13, 2011
- JCR: EPO Biosimilar Props Up Business
June 13, 2011
- Patent Office to Resume Discussions on Patent Extension for DDS Formulations
June 13, 2011
- Korosho Approves Kowa's Menstrual Pain Relieving Agents as Class 1 OTC Drug
June 13, 2011
- Lilly Transfers Evista to Takeda in 7 Asian Markets
June 13, 2011
- Promotion Office Discussing Establishment of “Drug Discovery Support Institute”
June 13, 2011
- Prof. Kadowaki to Collect Evidence under Intensified Therapy Using Incretin-related Drugs
June 13, 2011
- Kyowa Kirin, Ferring to Copromote Desmopressin ODT for Enuresis
June 13, 2011
- Korosho to Make Unapproved Drugs under Development Available for Use
June 13, 2011
- Nippon Shinyaku to Market 3 PH Treatments Mid-decade
June 13, 2011
- Rights to PD Treatment KW-6002 in North America Returned to Kyowa Kirin
June 13, 2011
- Ono, DSP to Codevelop CTS as Additional Indication for Limaprost
June 13, 2011
- Bendamustine to Be Marketed by Eisai in South Korea: SymBio
June 13, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…